Legend Biotech Corporation (FRA:9LB)
Germany · Delayed Price · Currency is EUR 17.70
-0.40 (-2.21%)
At close: Aug 26, 2026
Legend Biotech Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,271 | 1,029 | 627.3 | 285.1 | 117.01 | 68.83 |
Revenue Growth | 59.55% | 64.02% | 120.03% | 143.66% | 70.00% | -8.23% |
Gross Profit Gross Profit Growth | 719.3 | 620.8 | 392.7 | 140.9 | 51.64 | 68.83 |
Operating Income Operating Income Growth | -52.8 | -136.5 | -305.1 | -528.1 | -458.05 | -394.02 |
Net Income Net Income Growth | -91.5 | -296.8 | -177 | -518.3 | -446.35 | -403.58 |
Earnings Per Share EPS Growth | -0.50 | -1.62 | -0.97 | -2.94 | -2.81 | -2.87 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
License License Growth | 107.18 | 83.8 | 138.4 | 35.16 | 50 | 65.4 |
Collaboration Collaboration Growth | 1,164 | 944.8 | 482.58 | 249.8 | 66.68 | - |
Other Service Other Service Growth | - | 0.3 | 6.26 | 0.18 | 0.33 | 3.42 |
Revenue (Total) Revenue (Total) Growth | 1,271 | 1,029 | 627.3 | 285.1 | 117.01 | 68.83 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 964.6 | 948.6 | 1,123 | 1,309 | 1,026 | 882.4 |
Total Debt Total Debt Growth | 278.2 | 413.7 | 350.6 | 328.67 | 284.53 | 122.97 |
Net Cash (Debt) Net Cash Growth | 686.4 | 534.9 | 772 | 980.05 | 741.12 | 759.43 |
Net Cash Growth | 18.42% | -30.71% | -21.23% | 32.24% | -2.41% | 51.28% |
Net Cash Per Share Net Cash Per Share Growth | 3.70 | 2.90 | 4.22 | 5.57 | 4.66 | 5.39 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -89.4 | -100.2 | -144 | -393.3 | -201.28 | -198.47 |
Capital Expenditures CapEx Growth | -32.4 | -28.6 | -14.1 | -20.1 | -20.93 | -42.2 |
Free Cash Flow Free Cash Flow Growth | -121.8 | -128.8 | -158.1 | -413.4 | -222.21 | -240.66 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 56.57% | 60.34% | 62.60% | 49.42% | 44.14% | 100.00% |
Operating Margin | -4.15% | -13.27% | -48.64% | -185.23% | -391.48% | -572.49% |
Pretax Margin | -4.42% | -27.47% | -25.20% | -182.46% | -380.94% | -591.63% |
Profit Margin | -7.20% | -28.85% | -28.22% | -181.80% | -381.48% | -586.38% |
FCF Margin | -9.58% | -12.52% | -25.20% | -145.00% | -189.91% | -349.67% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 3.09 | 3.90 | 9.52 | 38.37 | 71.42 | 104.26 |